Quantitative analysis of keratin 18 in the urine of patients with bladder cancer

W. C. Baker; Ralph W deVere White; P. V. Rossitto; B. H. Min; Robert Cardiff

Quantitative analysis of keratin 18 in the urine of patients with bladder cancer

W. C. Baker, Ralph W deVere White, P. V. Rossitto, B. H. Min, Robert Cardiff

Research output: Contribution to journal › Article

Abstract

The level of urinary keratin was compared in patients with and without bladder cancer using the newly developed IRMAK-18. Patients with bladder cancer had higher levels of keratin (74.6 ± 146.9) than normals (2.5 ± 4.7). When the upper limit of normal was set at keratin <20 ng./ml., the test was highly specific (98%) for bladder cancer but had a sensitivity of only 46%. Adjusting to keratin <10 ng./ml. increased the sensitivity to 57% but decreased the specificity to 91%. Elevated keratins were associated with stage and grade, aneuploidy and disease history. The IRMAK-18 assay for keratin may be useful for monitoring the clinical progress of some patients.

Original language	English (US)
Pages (from-to)	436-439
Number of pages	4
Journal	Journal of Urology
Volume	140
Issue number	2
State	Published - 1988

ASJC Scopus subject areas

Urology

Access to Document

Fingerprint Dive into the research topics of 'Quantitative analysis of keratin 18 in the urine of patients with bladder cancer'. Together they form a unique fingerprint.

Cite this

@article{731e9d7b333241a6ac79616ace083abf,

title = "Quantitative analysis of keratin 18 in the urine of patients with bladder cancer",

abstract = "The level of urinary keratin was compared in patients with and without bladder cancer using the newly developed IRMAK-18. Patients with bladder cancer had higher levels of keratin (74.6 ± 146.9) than normals (2.5 ± 4.7). When the upper limit of normal was set at keratin <20 ng./ml., the test was highly specific (98%) for bladder cancer but had a sensitivity of only 46%. Adjusting to keratin <10 ng./ml. increased the sensitivity to 57% but decreased the specificity to 91%. Elevated keratins were associated with stage and grade, aneuploidy and disease history. The IRMAK-18 assay for keratin may be useful for monitoring the clinical progress of some patients.",

author = "Baker, {W. C.} and {deVere White}, {Ralph W} and Rossitto, {P. V.} and Min, {B. H.} and Robert Cardiff",

year = "1988",

language = "English (US)",

volume = "140",

pages = "436--439",

journal = "Journal of Urology",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Quantitative analysis of keratin 18 in the urine of patients with bladder cancer

AU - Baker, W. C.

AU - deVere White, Ralph W

AU - Rossitto, P. V.

AU - Min, B. H.

AU - Cardiff, Robert

PY - 1988

Y1 - 1988

N2 - The level of urinary keratin was compared in patients with and without bladder cancer using the newly developed IRMAK-18. Patients with bladder cancer had higher levels of keratin (74.6 ± 146.9) than normals (2.5 ± 4.7). When the upper limit of normal was set at keratin <20 ng./ml., the test was highly specific (98%) for bladder cancer but had a sensitivity of only 46%. Adjusting to keratin <10 ng./ml. increased the sensitivity to 57% but decreased the specificity to 91%. Elevated keratins were associated with stage and grade, aneuploidy and disease history. The IRMAK-18 assay for keratin may be useful for monitoring the clinical progress of some patients.

AB - The level of urinary keratin was compared in patients with and without bladder cancer using the newly developed IRMAK-18. Patients with bladder cancer had higher levels of keratin (74.6 ± 146.9) than normals (2.5 ± 4.7). When the upper limit of normal was set at keratin <20 ng./ml., the test was highly specific (98%) for bladder cancer but had a sensitivity of only 46%. Adjusting to keratin <10 ng./ml. increased the sensitivity to 57% but decreased the specificity to 91%. Elevated keratins were associated with stage and grade, aneuploidy and disease history. The IRMAK-18 assay for keratin may be useful for monitoring the clinical progress of some patients.

UR - http://www.scopus.com/inward/record.url?scp=0023801713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023801713&partnerID=8YFLogxK

M3 - Article

C2 - 2456406

AN - SCOPUS:0023801713

VL - 140

SP - 436

EP - 439

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -